We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OSR:HAMOSRAM Licht AG Analysis

Data as of 2026-03-17 - not real-time

CHF 8.38

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

ams-OSRAM AG posted Q4 results that slightly beat expectations and announced a €200 million savings program, while its core semiconductor portfolio grew 7% YoY and adjusted EBITDA margin improved by 1.5 percentage points. Despite these positive headlines, the company still grapples with a negative profit margin (-3.9%), high debt‑to‑equity (over 300%), and a ROE of -11.8%, indicating weak profitability and leverage concerns. Valuation metrics show a forward P/E of 8.7 versus an industry average of 34, a price‑to‑book near parity (0.98), and a DCF‑derived fair value that is only marginally above the current price, suggesting the stock is fairly valued at best.
Technical indicators are mixed: the 20‑day SMA (8.32) sits just below the market price (8.38), the MACD histogram is negative, and the RSI is neutral at 53, while volume is trending higher. High 30‑day volatility (~48%) and a beta below 1 point to moderate market sensitivity. Considering the earnings beat, cost‑cutting initiative, and sector dynamics, the short‑term outlook is cautious, but the medium‑term outlook improves if the savings program translates into stronger cash flow and debt reduction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Q4 earnings beat but still negative profitability
  • Bearish MACD and high volatility
  • Elevated debt level limiting flexibility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • €200 million savings program targeting cost efficiency
  • 7% YoY growth in core semiconductor segment
  • Attractive forward P/E relative to industry peers

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term demand for LED and optical sensor solutions
  • Debt reduction trajectory uncertain
  • Stable valuation metrics with limited upside

Key Metrics & Analysis

Financial Health

Revenue Growth-0.80%
Profit Margin-3.91%
P/E Ratio8.7
ROE-11.82%
ROA1.50%
Debt/Equity326.79
P/B Ratio1.0
Op. Cash FlowCHF237.0M
Free Cash FlowCHF258.5M
Industry P/E34.2

Technical Analysis

TrendNeutral
RSI52.8
SupportCHF 7.35
ResistanceCHF 9.11
MA 20CHF 8.32
MA 50CHF 8.28
MA 200CHF 9.55
MACDBearish
VolumeIncreasing
Fear & Greed Index79.45

Valuation

Fair ValueCHF 18.99
Target PriceCHF 8.20
Upside/Downside-2.06%
GradeFair
TypeBlend

Risk Assessment

Beta0.84
Volatility48.62%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.